Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Santarus has reported positive results from a recently completed clinical trial with immediate-release Zegerid capsules 40mg/1100mg and two leading proton pump inhibitors, Protonix delayed-release tablets 40mg and Prevacid delayed-release capsules 30mg.
Subscribe to our email newsletter
The primary endpoint of the open-label, randomized, crossover study was to evaluate the effects of morning dosing of Zegerid capsules, Protonix tablets and Prevacid capsules on 24-hour gastric acid control in patients with symptoms of gastroesophageal reflux disease (GERD), by measuring the percent time gastric pH was greater than 4.
The study data indicated that the percent time gastric pH was greater than 4 for patients taking Zegerid was approximately 43% longer than patients treated with Protonix (p<0.001) and approximately 22% longer than patients treated with Prevacid (p=0.005). Gerald Proehl, president and CEO of Santarus, said: "We believe these positive clinical results, together with the favorable results of our previously conducted studies, support the benefits of treating gastroesophageal reflux disease patients with Zegerid for both daytime and nighttime acid control."